Want to see SE:IMMNOV full AI Analyst Report?
IMMNOV Stock Chart & Stats
kr0.16
>-kr0.01(-5.58%)
At close: 4:00 PM EDT
kr0.16
>-kr0.01(-5.58%)
Day’s Range― - ―
52-Week Rangekr0.14 - kr0.75
Previous CloseN/A
Volume5.99M
Average Volume (3M)5.10M
Market Cap
kr102.78M
Enterprise Valuekr99.54
Total Cash (Recent Filing)kr34.90M
Total Debt (Recent Filing)kr3.27M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Nov 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding672,666,900
10 Day Avg. Volume6,199,351
30 Day Avg. Volume5,096,607
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)kr3.00M
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceRobust pooled sensitivity (83.3%) and specificity (~92%) for early‑stage pancreatic cancer gives the platform clinical credibility. Durable diagnostic accuracy supports payer discussions, guideline adoption in high‑risk surveillance programs, and differentiation versus competitors over the next 2–6 months.
Commercial Traction With Leading CentersAdoption by top academic centers and pipeline expansion (71→110+ centers) indicate scalable demand from influential referral hubs. Persistent engagement from leading centers and added field reps create a durable foundation for protocol adoption, referral volumes, and downstream commercial scale.
Low Financial LeverageLow leverage and a modest asset base provide balance‑sheet flexibility to pursue partnerships or structured financing without immediate debt strain. For a capital‑intensive clinical scale-up, this structural financial position supports strategic options and reduces bankruptcy risk over the medium term.
Bears Say
Minimal Revenue And Large LossesAbsolute revenue remains negligible versus expenses, with deeply negative margins and substantial cumulative losses. The cost base materially exceeds current sales, meaning durable path to breakeven requires sustained volume growth or structural cost reduction, posing execution risk for 2–6 month planning horizons.
Short Cash RunwayWith runway only into Q4 2026 at current burn, management must secure financing or partnerships to sustain operations. Near‑term capital raises can dilute equity and draw management focus to funding rather than commercial execution, raising structural execution risk as the company scales.
Reimbursement UncertaintyUnclear reimbursement rates, limited Medicare population scope, and slow private payer feedback constrain addressable revenue and margin sustainability. Structural uncertainty around realized pricing and coverage levels will materially affect long‑term unit economics and adoption beyond early academic sites.
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.14 and its highest was kr0.75 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr102.78M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 05, 2026 which is in 70 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 06, 2026. The company reported -kr0.03 earnings per share for the quarter, beating the consensus estimate of -kr0.04 by kr0.01.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.02.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.03 in its last earnings report, beating expectations of -kr0.04. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMNOV Company Deck
IMMNOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial, scientific and reimbursement progress: a successful product launch, strong clinical publications and podium presence, an awarded Medicare pricing of USD 897, state approvals in 48 states, targeted hiring of account managers, and a completed rights issue that improved cash position. However, near-term revenue remains limited, full payer coverage is not yet granted, cash runway extends only to Q3 2026 without additional capital, and realized per-test pricing and collections are still uncertain. The company emphasized disciplined spending, planned clinical utility data collection (including a 400-patient registry) and a mid-2026 Medicare submission with rolling data updates to mitigate coverage risk.View all SE:IMMNOV earnings summariesTechnical Analysis
Biosergen AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―